Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: Aripiprazole versus standard of care

Journal of Clinical Psychiatry

Volumn 69, Issue 5, 2008, Pages 741-748

  Blonde, Lawrence ^a   Kan, Hong J ^b   Gutterman, Elane M ^c   L'Italien, Gilbert J ^b,d   Kim, Myoung S ^b,f   Hanssens, Linda ^b   McQuade, Robert D ^e  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c Health Data Analytics   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^f Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; GLUCOSE; INSULIN; LIPID; OLANZAPINE; ORAL ANTIDIABETIC AGENT; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE MODEL; FEMALE; GLUCOSE TOLERANCE TEST; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; POPULATION; POST HOC ANALYSIS; PREDICTION; PRIORITY JOURNAL; RISK; RISK ASSESSMENT; RISK REDUCTION; SAMPLE; SCHIZOPHRENIA;

EID: 45249112569     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0507     Document Type: Article

References (44)

1. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000;177:212-217
2. Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000 Sep;45(1-2):21-28
3. Osby U, Correia N, Brandt L, et al. Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. BMJ 2000 Aug;321(7259):483-484
4. Enger C, Weatherby L, Reynolds RF, et al. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis 2004 Jan;192(1):19-27
5. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of 10-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005 Dec;80(1):45-53
6. Haupt DW, Newcomer JW. Abnormalities in glucose regulation associated with mental illness and treatment. J Psychosom Res 2002 Oct;53(4):925-933
7. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005 Aug 29;80:19-32
8. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005 Dec;150(6):1115-1121
9. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004 Feb;27(2):596-601
10. Newcomer JW. Second-Generation (Atypical) Antipsychotics and Metabolic Effects: A Comprehensive Literature Review. CNS Drugs 2005;19(suppl 1):1-93
11. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res 2004 Dec;71(2-3):195-212
12. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 Sep;353(12):1209-1223
13. McQuade RD, Kostic D, Marcus R, et al. Aripiprazole versus olanzapine in schizophrenia: a 52-week, open-label extension study. In: Abstracts of the 43rd annual meeting of the American College of Neuropsychopharmacology; Dec 12-16, 2004; San Juan, Puerto Rico. 173-174
14. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004 Sep;70(1):1-17
15. Almeras N, Despres JP, Villeneuve J, et al. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry 2004 Apr;65(4):557-564
16. Koro CE, Fedder DO, L'Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002 Nov;59(11):1021-1026
17. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002;325(7358):243-247
18. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003 Sep;64(9):1048-1056
19. McQuade RD, Radhakrishnan M, Stock E, et al. Investigator assessment of clinical parameters after initiating aripiprazole therapy. Presented at the 158th annual meeting of the American Psychiatric Association; May 21-26, 2005; Atlanta, Ga
20. Kerwin R, Millet B, Herman E, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients. Schizophrenia Trial of Aripiprazole: (STAR) Study [published online ahead of print Jun 5, 2007]. Eur Psychiatry 2007 Oct;22(7):433-443. doi: 10.1016/j.eurpsy.2007.03.002
21. Tandon R, Devellis RF, Han J, et al. Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatry Res 2005 Sep;136(2-3):211-221
22. Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 2002 Apr;136(8):575-581
23. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998 May;97(18):1837-1847
24. American Diabetes Association. Standards of Medical Care in Diabetes: 2007. Diabetes Care 2007 Jan;30(suppl 1):S4-S41
25. Kelly C, McCreadie RG. Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. Am J Psychiatry 1999 Nov;156(11):1751-1757
26. Osiri M, Suarez-Almazor ME, Wells GA, et al. Number needed to treat (NNT): implication in rheumatology clinical practice. Ann Rheum Dis 2003 Apr;62(4):316-321
27. McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004;65(suppl 18):47-56
28. Barnett AH, Mackin P, Chaudhry I, et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol 2007 Jun;21(4):357-373
29. De Nayer A, De Hert M, Scheen A, et al. Conference report: Belgian consensus on metabolic problems associated with atypical antipsychotics. Encephale 2007 Mar-Apr;33(2):197-202
30. De Hert M, Hanssens L, van Winkel R, et al. A case series: evaluation of the metabolic safety of aripiprazole. Schizophr Bull 2007 Aug; 33(33):823-830
31. Kim SH, Ivanova O, Abbasi FA, et al. Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study. J Clin Psychopharmacol 2007 Aug;27(4):365-368
32. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003;26(3):917-932
33. Chrzanowski WK, Marcus RN, Torbeyns A, et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl) 2006 Dec;189(2):259-266
34. D'Agostino RB Sr, Grundy S, Sullivan LM, et al. Validation of the Framingham Coronary Heart Disease Prediction scores: results of a multiple ethnic groups investigation. JAMA 2001 Jul;286(2):180-187
35. Ramachandran S, French JM, Vanderpump MP, et al. Using the Framingham model to predict heart disease in the United Kingdom: retrospective study. BMJ 2000 Mar;320(7236):676-677
36. Brindle P, Emberson J, Lampe F, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 2003 Nov;327(7426):1267
37. Hense HW, Schulte H, Lowel H, et al. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany: results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J 2003 May;24(10):937-945
38. Thomsen TF, McGee D, Davidsen M, et al. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol 2002 Aug;31(4):817-822
39. Rathmann W, Martin S, Haastert B, et al. Performance of screening questionnaires and risk scores for undiagnosed diabetes: the KORA Survey 2000. Arch Intern Med 2005 Feb 28;165(4):436-441
40. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003 Feb;160(2):284-289
41. Valenstein M, Ganoczy D, McCarthy JF, et al. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry 2006 Oct;67(10):1542-1550
42. Herran A, de Santiago A, Sandoya M, et al. Determinants of smoking behaviour in outpatients with schizophrenia. Schizophr Res 2000 Jan; 41(2):373-381
43. Tandon R, Marcus RN, Stock EG, et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res 2006 May;84(1):77-89
44. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003 Jul;60(7):681-690